260 related articles for article (PubMed ID: 18781944)
21. Understanding the binding of inhibitors of matrix metalloproteinases by molecular docking, quantum mechanical calculations, molecular dynamics simulations, and a MMGBSA/MMBappl study.
Singh T; Adekoya OA; Jayaram B
Mol Biosyst; 2015 Apr; 11(4):1041-51. PubMed ID: 25611160
[TBL] [Abstract][Full Text] [Related]
22. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
Levin M; Udi Y; Solomonov I; Sagi I
Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
[TBL] [Abstract][Full Text] [Related]
23. [Design, synthesis and activity evaluation of novel matrix metalloproteinases inhibitors based on the structure of enzyme].
Jia H; Guo YS; Ge YY; Wen H; Yang J; Yang XY; Du GH; Yang GZ
Yao Xue Xue Bao; 2007 Dec; 42(12):1271-81. PubMed ID: 18338640
[TBL] [Abstract][Full Text] [Related]
24. Matrix metalloproteinases.
Zitka O; Kukacka J; Krizkova S; Huska D; Adam V; Masarik M; Prusa R; Kizek R
Curr Med Chem; 2010; 17(31):3751-68. PubMed ID: 20846107
[TBL] [Abstract][Full Text] [Related]
25. Characterization of matrix metalloproteinase inhibitors: enzymatic assays.
Marcotte PA; Davidsen SK
Curr Protoc Pharmacol; 2001 Aug; Chapter 3():Unit3.7. PubMed ID: 21959756
[TBL] [Abstract][Full Text] [Related]
26. The Significance of Matrix Metalloproteinases in Oral Diseases.
Maciejczyk M; Pietrzykowska A; Zalewska A; Knaś M; Daniszewska I
Adv Clin Exp Med; 2016; 25(2):383-90. PubMed ID: 27627574
[TBL] [Abstract][Full Text] [Related]
27. Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.
Georgiadis D; Yiotakis A
Bioorg Med Chem; 2008 Oct; 16(19):8781-94. PubMed ID: 18790648
[TBL] [Abstract][Full Text] [Related]
28. Matrix Metalloproteinases: A challenging paradigm of cancer management.
Alaseem A; Alhazzani K; Dondapati P; Alobid S; Bishayee A; Rathinavelu A
Semin Cancer Biol; 2019 Jun; 56():100-115. PubMed ID: 29155240
[TBL] [Abstract][Full Text] [Related]
29. Targeting matrix metalloproteinases: design of a bifunctional inhibitor for presentation by tumour-associated galectins.
Bartoloni M; Domínguez BE; Dragoni E; Richichi B; Fragai M; André S; Gabius HJ; Ardá A; Luchinat C; Jiménez-Barbero J; Nativi C
Chemistry; 2013 Feb; 19(6):1896-902. PubMed ID: 23280962
[TBL] [Abstract][Full Text] [Related]
30. Biochemical and Biological Attributes of Matrix Metalloproteinases.
Cui N; Hu M; Khalil RA
Prog Mol Biol Transl Sci; 2017; 147():1-73. PubMed ID: 28413025
[TBL] [Abstract][Full Text] [Related]
31. Matrix metalloproteinase inhibitors: a review on bioanalytical methods, pharmacokinetics and metabolism.
Wang X; Li KF; Adams E; Van Schepdael A
Curr Drug Metab; 2011 May; 12(4):395-410. PubMed ID: 21395524
[TBL] [Abstract][Full Text] [Related]
32. Activation and silencing of matrix metalloproteinases.
Fu X; Parks WC; Heinecke JW
Semin Cell Dev Biol; 2008 Feb; 19(1):2-13. PubMed ID: 17689277
[TBL] [Abstract][Full Text] [Related]
33. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
[TBL] [Abstract][Full Text] [Related]
34. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis.
Leppert D; Lindberg RL; Kappos L; Leib SL
Brain Res Brain Res Rev; 2001 Oct; 36(2-3):249-57. PubMed ID: 11690622
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinases and the thyroid.
Kraiem Z; Korem S
Thyroid; 2000 Dec; 10(12):1061-9. PubMed ID: 11201850
[TBL] [Abstract][Full Text] [Related]
36. Design and Structural Evolution of Matrix Metalloproteinase Inhibitors.
Fischer T; Senn N; Riedl R
Chemistry; 2019 Jun; 25(34):7960-7980. PubMed ID: 30720221
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms to inhibit matrix metalloproteinase activity: where are we in the development of clinically relevant inhibitors?
Corbitt CA; Lin J; Lindsey ML
Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):135-42. PubMed ID: 18221058
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
[TBL] [Abstract][Full Text] [Related]
39. Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.
Sawa M; Kondo H; Nishimura S
Bioorg Med Chem Lett; 2002 Feb; 12(4):581-4. PubMed ID: 11844676
[TBL] [Abstract][Full Text] [Related]
40. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
Clin Chem Lab Med; 2004 Feb; 42(2):121-31. PubMed ID: 15061349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
